Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 256.36%.

  • InMed Pharmaceuticals' EBITDA Margin fell 547000.0% to 256.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 174.33%, marking a year-over-year decrease of 124500.0%. This contributed to the annual value of 159.76% for FY2025, which is 174700.0% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' EBITDA Margin is 256.36%, which was down 547000.0% from 162.54% recorded in Q3 2025.
  • InMed Pharmaceuticals' EBITDA Margin's 5-year high stood at 20.43% during Q2 2023, with a 5-year trough of 1615.6% in Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 193.24% (2023), whereas its average is 460.38%.
  • As far as peak fluctuations go, InMed Pharmaceuticals' EBITDA Margin soared by 15084400bps in 2023, and later crashed by -1376900bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBITDA Margin stood at 1615.6% in 2021, then surged by 72bps to 447.25% in 2022, then skyrocketed by 71bps to 131.49% in 2023, then plummeted by -53bps to 201.65% in 2024, then decreased by -27bps to 256.36% in 2025.
  • Its last three reported values are 256.36% in Q4 2025, 162.54% for Q3 2025, and 138.56% during Q2 2025.